Sacituzumab tirumotecan–pembrolizumab has efficacy in PD-L1-negative NSCLC
Nature · By Diana Romero ·
Nature Reviews Clinical Oncology, Published online: 06 November 2026; doi:10.1038/s41571-026-01232-0 Sacituzumab tirumotecan–pembrolizumab has efficacy in PD-L1-negative NSCLC